Envista Holdings presented its outlook on Tuesday, September 15, at the 2026 Global Healthcare Conference, hosted by senior medical‑technology analyst Jeff Johnson of Baird. The company, whose market capitalization stands at $4.05 billion, reported trailing‑twelve‑month revenue growth of nearly 12% and a price‑to‑earnings multiple of 44.16, with a PEG ratio of 0.52 suggesting valuation upside relative to growth.
Gross profit margin was disclosed at 55.42%, while consolidated dental pricing inflation is running at about 1.8%, above the long‑term range of 1.0%‑1.5%. The stock has delivered an 18.79% gain year‑to‑date, closing the session at $25.55, down 1.24%, and trading at $25.61 after hours, up 0.22%.
Geographically, roughly 75% of Envista’s revenue derives from North America, where both equipment and consumables are expanding at high single‑digit rates. In the United States, private insurers reimburse about 60% of dental consumables. The implant segment is split 85% premium and 15% challenger products; premium implants are growing in the low single digits, while challenger implants are expanding faster, a mix the company plans to increase deliberately. The global implant market is expanding in the mid‑single‑digit range, and diagnostics are growing in the mid‑to‑high single digits, expected to settle back to low single digits over time.
Regional growth priorities place developing markets (excluding China) at the top, with double‑digit implant growth anticipated, followed by Europe (mid‑single digits), North America (low single digits) and China (slowest due to value‑based procurement). In China, Envista holds about a 30% share of the implant market and is the leading orthodontics supplier. Public hospitals represent 40% of the Chinese dental market, with private hospitals covering the remaining 60%. Value‑based procurement (VBP) rounds are expected to cut orthodontics prices by 40%‑50% for winning suppliers and implant prices by 10%‑20%. The first half of 2026 saw a year‑over‑year decline in the China business, with a projected $10 million orthodontics inventory drawdown in Q3 that should largely reverse in Q4.
The company has completed three small bolt‑on implant acquisitions in the past 18 months. Envista’s acquisition framework, described as the “Bullseye,” requires targets to grow faster than Envista, deliver higher margins than the consolidated business, and be purchasable at a multiple below Envista’s current trading multiple.
CEO Paul Keel emphasized the workflow‑centric model, stating that the company sells the end‑to‑end process rather than individual screws. He reiterated the Bullseye criteria for accretive deals and expressed optimism about VBP outcomes, noting that high‑share suppliers can emerge with greater market share and volume after the procurement process.
Analyst sentiment remains positive, with 11 analysts raising earnings forecasts and InvestingPro assigning a “GOOD” financial‑health rating to the stock.
